BioSpace News Archive

BioConnect is pleased to announce Debbie Landers, a former IBM Executive has joined BioConnect’s Advisory Board to assist with the strategic development of the company.

Small nonprofits are eager for government action on health care, but they’re split over whether a “Medicare for All"-style policy is the right answer.

Heritage Pharmaceuticals Inc. issued the following statement regarding its recent agreement with the United States Department of Justice, Antitrust Division (“DOJ”) that was announced on May 31, 2019:

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new subgroup analysis from the landmark phase 3 CREDENCE study, showing INVOKANA® (canagliflozin) significantly reduced the risk of major cardiovascular (CV) events and kidney failure in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD)

Four abstracts presented including first-in-human results in liver tumors and preclinical evidence of histotripsy-induced immune response using novel sonic beam therapy

For people with type 2 diabetes (T2D) and chronic kidney disease (CKD), canagliflozin, an oral, sodium-glucose co-transporter-2 (SGLT2) inhibitor, has a renal- and cardiovascular-protective effect in reducing the progression of kidney impairment, according to the results of the CREDENCE trial presented today in a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco.

First Hospital in Kentucky to Offer Blue Dot Indoor Navigation

ValueHealth CEO Carl King announced the hiring of Dallas Scrip as President of Benefit Management.

Rodan & Fields, LLC, a prestige, dermatology-inspired skincare brand, and the #1 skincare brand in North America1, will present three Scientific Posters at this year’s 24th World Congress of Dermatology meeting held in Milan.

NYU Langone Health will partner with The American Journal of Managed Care® (AJMC®) and NeurologyLive™